A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants with Type 2 Diabetes during Ramadan (T-RAM)

drug protocol number
I8F-MC-GPIY
drug sponsor
Eli Lilly
drug study
Tirzepatide
drug trial site
Al Moosa Specialized Hospital (al ahsa)
drug status
Ongoing
drug phase